Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1260"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1714"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_numb_subjects	"17"
?:Evidence_object_dose	"0.05"
?:Evidence_precip_dose	"0.2"
?:Evidence_type	?:EV_PK_DDI_NR
?:Evidence_value	"0"
?:content	"Route of administration: oral study duration: three weeks population: 17 patients stabilized on clozapine, eight of which received sertraline for an additional three weeks ages: 29 - 55 Quote: The effect of paroxetine or sertraline on steady-state plasma concentrations of clozapine and its major metabolites was studied in 17 patients with schizophrenia or schizoaffective disorder stabilized on clozapine therapy (200-400 mg/day). In order to treat negative symptomatology or concomitant depression, 9 patients received additional paroxetine (20-40mg/day) and 8 patients sertraline (50-100 mg/day). After 3 weeks of paroxetine administration, mean plasma concentrations of clozapine and norclozapine increased significantly by 31% (p<0.01) and by 20% (p<0.05), respectively, while levels of clozapine N-oxide remained almost unchanged. The mean plasma norclozapine/clozapine and clozapine N-oxide/clozapine ratios were not modified during paroxetine treatment. No significant changes in plasma concentrations of clozapine and its major metabolites were observed after 3 weeks of combined therapy with sertraline."
dc:creator	"boycer"
dc:date	"06/16/2009 12:01:53"
rdfs:seeAlso	?:11147928

The resource appears as object in one triple:

{ sertraline_increases_auc_clozapine-N-oxide, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1714 }

Context graph